This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bruker (BRKR) Banks on End Market Growth Amid Macro Headwinds
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Bruker (BRKR) Expands in NMR Spectrometry With New FMP Collab
by Zacks Equity Research
Bruker (BRKR) completes the installation of its 1.2 (GHz) Avance nuclear magnetic resonance (NMR) spectrometer at the Leibniz Forschungsinstitut f??r Molekulare Pharmakologie in Berlin.
Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes
by Zacks Equity Research
Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
by Zacks Equity Research
Bruker's (BRKR) neofleX is a versatile, high-performance and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
by Zacks Equity Research
Bruker's (BRKR) BSI Nano business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.
Zacks Industry Outlook Highlights Mettler-Toledo and Bruker
by Zacks Equity Research
Mettler-Toledo and Bruker have been highlighted in this Industry Outlook article.
2 Instruments Stocks to Watch From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
Investing in Bruker (BRKR)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Examine Bruker's (BRKR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Down -22.53% in 4 Weeks, Here's Why Bruker (BRKR) Looks Ripe for a Turnaround
by Zacks Equity Research
Bruker (BRKR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline
by Zacks Equity Research
Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.
Bruker (BRKR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Bruker (BRKR) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Are Computer and Technology Stocks Lagging Alphabet (GOOGL) This Year?
by Zacks Equity Research
Here is how Alphabet (GOOGL) and Bruker (BRKR) have performed compared to their sector so far this year.
Bruker (BRKR) Q1 Earnings Beat Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 15.22% and 0.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
by Urmimala Biswas
Here is a sneak peek into how the five MedTech stocks, HOLX, ZBH, ILMN, TFX and BRKR, are expected to fare in their quarterly results slated to be released tomorrow.
Countdown to Bruker (BRKR) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Bruker (BRKR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Here's Why You Should Buy Bruker (BRKR) Stock Right Now
by Zacks Equity Research
Bruker's (BRKR) strong potential across the NANO and BioSpin segments bodes well for investors.
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
by Zacks Equity Research
Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.
Earnings Preview: Bruker (BRKR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
by Zacks Equity Research
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.